Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Modulight

1.02 EUR-1.92 %1.9, 17.25
2,823 following

MODU

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-1.92 %
-2.86 %
-18.07 %
-8.44 %
-8.93 %
-23.88 %
-41.91 %
-
-90.68 %

Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.

Read more
Market cap
43.47M EUR
Turnover
18.11K EUR
P/E (adj.) (26e)
-8.95
EV/EBIT (adj.) (26e)
-8.11
EV/S (26e)
5.61
Dividend yield-% (26e)
-
Coverage
Recommendation
Reduce
Target price
1.10 EUR
Updated
23.08.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 24.08.2026

Latest extensive report

Released: 01.07.2025

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
Just to avoid any misunderstandings: I spend exactly as much time on Modulight’s analysis as it requires. The company’s performance/development has nothing to do with motivation or webcast attendance, even though this time the questions were left unasked due to technical issues. ...
8/24/2026, 8:48 AM
by Antti Siltanen
16
I am not surprised that there is no interest. Read through all the materials from the initial public offering (IPO), and you will notice that the information provided by the company at the time regarding profitability and future forecasts was completely unrealistic. Compare that ...
8/24/2026, 7:17 AM
by Nordman09
13
A bit late again in getting around to diving into the H1 report and Orsila’s interview. For me, this has been a quite interesting investment story and on my watchlist for several years already. I’ve been pondering these three (light-strategic) risks a bit… Please throw in some good...
8/26/2026, 6:09 PM
by PerusPiensijoittaja
6
Interest in Modulight has really faded. It seems like only one user asked two questions, and not even a single analyst could be bothered to show up​
8/21/2026, 6:36 PM
by NOKNOK
6
Well, yeah, if I remember correctly, Modulight’s strategy has relied on biomedicine starting from 2014, so in that respect, there haven’t been changes. The IPO proceeds were largely used to build a new production facility, but there was in-house production even before that, so no...
8/25/2026, 12:58 PM
by Antti Siltanen
4
Antti haastatteli Modulightin toimitusjohtaja Seppo Orsilaa Q2:n tiimoilta Aiheet: (00:00) Aloitus (00:09) Kvartaalin kuulumiset (00:56) Aura Biosciences (01:48) PPT-liikevaihdon kasvu (04:06) Kvanttiteknologia-asiakkaat (05:40) Ohjeistukseen pääseminen (07:12) Tuotantolaitoksen ...
8/21/2026, 2:02 PM
by Sijoittaja-alokas
3
Fortunately, the company seems to take the adequacy of its cash reserves genuinely seriously. Interest in the company is so non-existent and liquidity is so thin that it would get ugly if the company were forced to raise more money through a share issue .
8/25/2026, 12:06 PM
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
23.10
2026

Interim report Q3'26

Modulight Q2'26: Pricing under pressure
Research24.08.2026, 10.20 by
Antti Siltanen

Modulight Q2'26: Pricing under pressure

Delays and pricing pressures burdened revenue development.

Modulight
Regulatory press release21.08.2026, 09.30

Modulight: Significant customer project advances toward commercialization

Modulight
Modulight Q2'26 preview: Savings measures likely to improve earnings while revenue declines
Analyst Comment19.08.2026, 09.22 by
Antti Siltanen

Modulight Q2'26 preview: Savings measures likely to improve earnings while revenue declines

We expect Q2 revenue to decline slightly from the comparison period, which was supported by the quantum computing project.

Modulight

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release14.08.2026, 09.00

Modulight to Publish Second Quarter and Half-Year Financial Report on August 21, 2026

Modulight
Regulatory press release05.06.2026, 10.42

Correction: 1Q26 Interim Report

Modulight
Regulatory press release04.05.2026, 14.55

Resolutions of Modulight Corporation’s Annual General Meeting and Inaugural Meeting of the Board of Directors on 4 May 2026

Modulight
Modulight Q1'26: Decreased costs improved profitability
Research27.04.2026, 09.53 by
Antti Siltanen

Modulight Q1'26: Decreased costs improved profitability

Modulight's Q1 revenue declined year-on-year and missed our estimate. On the other hand, earnings and cash flow were better than we expected.

Modulight
Regulatory press release24.04.2026, 09.30

Modulight: Profitability improved despite the decline in revenue

Modulight
Modulight issued guidance for 2026
Analyst Comment22.04.2026, 07.28 by
Antti Siltanen

Modulight issued guidance for 2026

We expect EBITDA to turn positive in 2026.

Modulight
Modulight Q1'26 preview: Steady progress supported by the PPT model
Analyst Comment22.04.2026, 08.13 by
Antti Siltanen

Modulight Q1'26 preview: Steady progress supported by the PPT model

We expect moderate growth, as the company has not announced any separate major deals.

Modulight
Regulatory press release21.04.2026, 14.21

Inside information: Modulight introduces financial guidance for 2026

Modulight
Regulatory press release17.04.2026, 13.51

Modulight Corporation: Managers' Transactions – Kati Reiman

Modulight
Press release17.04.2026, 09.30

Modulight to publish its interim report for January–March 2026 on April 24, 2026

Modulight
Regulatory press release07.04.2026, 11.30

Notice To Modulight Corporation's Annual General Meeting

Modulight
Regulatory press release27.03.2026, 15.45

Proposals of the Shareholders’ Nomination Board of Modulight to the Annual General Meeting 2026

Modulight
US market roadmap for medical devices – a European perspective
Analyst Comment27.03.2026, 11.45 by
Antti Siltanen

US market roadmap for medical devices – a European perspective

Success in the US requires success in several sub-areas.

BioretecAiforia TechnologiesNightingale HealthNexstimOptomedRevenio GroupModulightBiohit
Regulatory press release13.03.2026, 12.00

Modulight’s Annual Report 2025 Published

Modulight
Modulight Q4'25: Small steps in the right direction
Research23.02.2026, 09.00 by
Antti Siltanen

Modulight Q4'25: Small steps in the right direction

Modulight's 2025 was characterized by growth.

Modulight
Regulatory press release20.02.2026, 10.00

Modulight: Record Year in Revenue Growth

Modulight
Regulatory press release20.02.2026, 09.59

Inside information: Modulight Corporation updates its strategy and sets new financial targets for the years 2026–2027

Modulight